Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Daratumumab improves PFS in elderly patients with multiple myeloma

Roshini Claire Anthony, 3 hours ago

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) led to improved progression-free survival (PFS) over VMP alone in elderly patients newly diagnosed with multiple myeloma (MM), reflecting the results of the overall ALCYONE* study population.

Segmentectomy on par with lobectomy for early NSCLC

2 days ago

Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.

Long-term data strengthen obinutuzumab as frontline CLL therapy

Pearl Toh, 2 days ago

A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.

High serum 25(OH)D protects against breast cancer

2 days ago

There appears to be a dose-response protective effect of serum concentrations of 25-hydroxyvitamin D (25(OH)D) on the risk of breast cancer, such that levels of ≥60 ng/mL yield the most protection, according to a recent study.

Long-term PDAC screening improves detection of resectable tumours in high-risk population

3 days ago

Continued follow-up study of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) leads to successful detection of resectable tumours and high-grade precursor neoplasms, as shown in a recent study.

Surgical resection superior to radiofrequency ablation for small perivascular HCC

3 days ago

Surgical resection (SR) as a first-line treatment for small perivascular hepatocellular carcinoma (HCC) provides better long-term tumour control than radiofrequency ablation (RFA), a recent study has shown.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

Highlights from ESMO Asia 2017: Moving to a dual blockade strategy early in hormone receptor-positive breast cancer

22 Jan 2018

In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.

Extending survival with sorafenib in locally advanced hepatocellular carcinoma

04 Dec 2017

Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.

Long-term data strengthen obinutuzumab as frontline CLL therapy

Pearl Toh, 22 Jun 2018

PET-driven strategy effective, reduces treatment toxicity in advanced Hodgkin lymphoma

Roshini Claire Anthony, 21 Jun 2018

Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.

Eltrombopag proven effective in chronic, persistent immune thrombocytopaenia

Stephen Padilla, 21 Jun 2018

Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.

ALCYONE: Daratumumab combo prolongs survival in multiple myeloma

Jairia Dela Cruz, 21 Jun 2018

A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Tisagenlecleucel improves QoL in paediatric, young adult RR B-ALL patients

Tristan Manalac, 21 Jun 2018

There appear to be significant improvements in patient-reported quality of life (QoL) following tisagenlecleucel infusion in paediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), according a study presented at the recent 23rd Congress of the European Haematology Association (EHA 2018).

High-dose esomeprazole plus aspirin can help prevent oesophageal carcinoma

Dr. Joseph Delano Fule Robles, 21 Jun 2018

High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).

Taselisib plus fulvestrant shows encouraging results for advanced breast cancer

Dr. Joseph Delano Fule Robles, 21 Jun 2018

The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!